Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma

Mansoura University

Status: Unknown

Conditions: Role of Serum Regucalcin in Diagnosis of HCC

Treatments: Diagnostic Test: serum regucalcin antibody

Study type: Observational

Funder types: Other

Identifiers

NCT03206866

SMP30

Details and patient eligibility

About

Although the diagnosis and therapy of HCC have being improved, the poor prognosis still remains. To reduce the mortality and improve the effectiveness of diagnosis and therapy, it is important to detect the protein biomarkers which are associated with HCC tumor progression and may be useful as potential diagnosis or therapeutic targets.

SMP30 (senescence marker protein 30)(serum regucalcin), which we have previously identified from Guangxi HCC cDNA expression library by the SEREX approach, is one of the hepatocellular carcinoma associated antigens [4]

Serum antibody response to SMP30 in various patients using the methods of Western-blot and ELISA and showed that antibody to SMP30 existed mainly in HCC patients (39.8%), especially in the one with alpha-fetoprotein (AFP) negative

Enrollment: 96 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Newly diagnosed cases of HCC (be based on NCCN guidelines triphasic CT and AFP or liver biopsy)
2. Adult patients
3. Both genders are eligible.
4. Informed consent obtained from subject or subject's legal representative

Exclusion criteria

1. Patient with other malignancies.
2. Patients with advanced comorbidities except for renal failure.
3. Prior chemotherapy

Trial design

96 participants in 3 patient groups

patients with HCC

Treatment:

Diagnostic Test: serum regucalcin antibody

patients with hepatitis C Ab positive

Treatment:

Diagnostic Test: serum regucalcin antibody

patients with hepatitis C Ab negative

Treatment:

Diagnostic Test: serum regucalcin antibody